Clinical and radiomic characteristics of transarterial chemoembolization combined with immunotherapy in hepatocellular carcinoma

doi:10.4240/wjgs.v18.i7.119397

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(4)

(3)

(0)

(17)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Jul 27, 2026; 18(7): 119397
Published online Jul 27, 2026. doi: 10.4240/wjgs.v18.i7.119397

Open in New Tab Full Size Figure Download Figure

Figure 1 Comparative imaging of the two patient groups before and after treatment. A: Preoperative transarterial chemoembolization (TACE) combined with immunotherapy; B: Postoperative TACE combined with immunotherapy; C: Preoperative TACE monotherapy; D: Postoperative TACE monotherapy.

Citation: Xia Q, Shan W, Yan H. Clinical and radiomic characteristics of transarterial chemoembolization combined with immunotherapy in hepatocellular carcinoma. World J Gastrointest Surg 2026; 18(7): 119397
URL: https://www.wjgnet.com/1948-9366/full/v18/i7/119397.htm
DOI: https://dx.doi.org/10.4240/wjgs.v18.i7.119397

Xia Q, Shan W, Yan H. Clinical and radiomic characteristics of transarterial chemoembolization combined with immunotherapy in hepatocellular carcinoma. World J Gastrointest Surg 2026; 18(7): 119397 [DOI: 10.4240/wjgs.v18.i7.119397]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.